Compare Dr. Reddys with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs LUPIN - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB LUPIN DR. REDDYS LAB/
LUPIN
 
P/E (TTM) x 34.8 40.5 86.0% View Chart
P/BV x 4.8 3.7 128.0% View Chart
Dividend Yield % 0.6 0.6 95.8%  

Financials

 DR. REDDYS LAB   LUPIN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
LUPIN
Mar-20
DR. REDDYS LAB/
LUPIN
5-Yr Chart
Click to enlarge
High Rs3,363882 381.2%   
Low Rs2,352505 465.7%   
Sales per share (Unadj.) Rs1,054.2339.4 310.6%  
Earnings per share (Unadj.) Rs121.9-5.9 -2,050.2%  
Cash flow per share (Unadj.) Rs190.215.5 1,229.5%  
Dividends per share (Unadj.) Rs25.006.00 416.7%  
Dividend yield (eoy) %0.90.9 101.1%  
Book value per share (Unadj.) Rs938.7276.7 339.2%  
Shares outstanding (eoy) m166.17453.00 36.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.72.0 132.6%   
Avg P/E ratio x23.4-116.6 -20.1%  
P/CF ratio (eoy) x15.044.8 33.5%  
Price / Book Value ratio x3.02.5 121.5%  
Dividend payout %20.5-100.9 -20.3%   
Avg Mkt Cap Rs m474,831314,201 151.1%   
No. of employees `00021.718.3 118.3%   
Total wages/salary Rs m33,80229,868 113.2%   
Avg. sales/employee Rs Th8,091.08,400.6 96.3%   
Avg. wages/employee Rs Th1,561.31,632.0 95.7%   
Avg. net profit/employee Rs Th935.8-147.2 -635.8%   
INCOME DATA
Net Sales Rs m175,170153,748 113.9%  
Other income Rs m6,2064,838 128.3%   
Total revenues Rs m181,376158,585 114.4%   
Gross profit Rs m24,42124,849 98.3%  
Depreciation Rs m11,3489,702 117.0%   
Interest Rs m9833,630 27.1%   
Profit before tax Rs m18,29616,355 111.9%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m56139 1,423.9%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m-1,40311,571 -12.1%   
Profit after tax Rs m20,260-2,694 -752.1%  
Gross profit margin %13.916.2 86.3%  
Effective tax rate %-7.770.8 -10.8%   
Net profit margin %11.6-1.8 -660.1%  
BALANCE SHEET DATA
Current assets Rs m125,991154,132 81.7%   
Current liabilities Rs m72,14192,252 78.2%   
Net working cap to sales %30.740.2 76.4%  
Current ratio x1.71.7 104.5%  
Inventory Days Days7382 89.0%  
Debtors Days Days105129 81.0%  
Net fixed assets Rs m83,85489,082 94.1%   
Share capital Rs m831906 91.7%   
"Free" reserves Rs m155,157124,461 124.7%   
Net worth Rs m155,988125,367 124.4%   
Long term debt Rs m1,30417,933 7.3%   
Total assets Rs m232,253249,839 93.0%  
Interest coverage x19.65.5 356.2%   
Debt to equity ratio x00.1 5.8%  
Sales to assets ratio x0.80.6 122.6%   
Return on assets %9.10.4 2,441.7%  
Return on equity %13.0-2.1 -604.4%  
Return on capital %12.68.7 144.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,19351,450 163.6%   
Fx outflow Rs m39,61619,470 203.5%   
Net fx Rs m44,57731,980 139.4%   
CASH FLOW
From Operations Rs m29,84114,688 203.2%  
From Investments Rs m-4,92311,070 -44.5%  
From Financial Activity Rs m-25,159-8,906 282.5%  
Net Cashflow Rs m-26616,853 -1.6%  

Share Holding

Indian Promoters % 25.5 46.6 54.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 31.9 110.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.1 151.5%  
Shareholders   75,885 98,259 77.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SHASUN PHARMA  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 5, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS